Drug development and potential regulatory paths for insulin biosimilars

Journal of Diabetes Science and Technology

Volumn 8, Issue 1, 2014, Pages 14-19

  Minocha, Mukul ^a   Gobburu, Jogarao ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Biosimilar; Drug development; Insulin; Interchangeability; Regulatory

Indexed keywords

BIOSIMILAR INSULIN; INSULIN; UNCLASSIFIED DRUG;

CLINICAL PHARMACOLOGY; CLINICAL STUDY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG DEVELOPMENT; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; NONHUMAN; SAMPLE SIZE; STUDY DESIGN;

EID: 84900554442     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296813516954     Document Type: Conference Paper

References (17)

1. Public Health Service. Biologics Price Competition and Innovation Act of 2009. 2009.
2. Rotenstein LS, Shivers JP, Yarchoan M, Close KL. Opportunities and challenges for biosimilars: what's on the horizon in the global insulin market? Clin Diabetes. 2012;30(4):12.
3. Rene. Global insulin sales to reach $32 bn in 2018. Available at: http://www.healthcarefinancenews.com/news/global-insulin-market-expected-reach- 32b-2018. Accessed November 23, 2013.
4. Food and Drug Administration. Applications Covered by Sections 505(b)(2). 1999.
5. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214- E223.
6. European Medicines Agency. Guideline on Non-clinical and Clinical Development of Similar Biological Medicinal Products Containing Recombinant Human Insulin and Insulin Analogues. 2012.
7. Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 2012.
8. Food and Drug Administration. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. 2008.
9. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614-1620.
10. Food and Drug Administration. Statistical Approaches to Establishing Bioequivalence. 2001.
11. Dubins. Free analysis research tool for sample size iterative estimation. Available at: http://individual.utoronto.ca/ddubins/. Accessed November 23, 2013.
12. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408-416.
13. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther. 2009;31(10):2086-2097.
14. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976- 1987.
15. Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients. Drug Metab Pharmacokinet. 2010;25(5):418-429.
16. Hamren B, Bjork E, Sunzel M, Karlsson M. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther. 2008;84(2):228-235.
17. Gobburu JV. Biomarkers in clinical drug development. Clin Pharmacol Ther. 2009;86(1):26-27.